Bank of New York Mellon
XLO icon

Bank of New York Mellon’s Xilio Therapeutics XLO Stock Holding History

Bank of New York Mellon’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,502
Closed -$149K – 4711
2022
Q1 		$149K Buy
1,502
+485
+48% +$76.7K ﹤0.01% 4326
2021
Q4 		$228K Buy
+1,017
New +$242K ﹤0.01% 4227

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Bank of New York Mellon's XLO Position: Q2 2022 in Review

Bank of New York Mellon sold out of Xilio Therapeutics (XLO) in Q2 2022, closing a stake of 1,502 shares — an estimated $149K sold.

Bank of New York Mellon first reported a position in XLO in Q4 2021 and held it in 2 quarters. The position peaked at $228K in Q4 2021. 32 funds tracked by Wall St. Rank hold XLO as of Q2 2022.

  • Bank of New York Mellon reported no remaining Xilio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bank of New York Mellon sold 1,502 Xilio Therapeutics shares in Q2 2022, an estimated $149K.
  • Bank of New York Mellon first reported a position in Xilio Therapeutics in Q4 2021 and held it in 2 quarters.
  • Bank of New York Mellon's Xilio Therapeutics position peaked at $228K in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.